VRCA - Verrica Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

87.64M

Cash

55.14M

Avg Qtr Burn

-3.097M

Short % of Float

24.31%

Insider Ownership

39.84%

Institutional Own.

31.10%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
YCANTH (VP-102) Details Infectious disease, Molluscum contagiosum	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Genital Warts	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Common Warts	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-315 Details Basal cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.